[go: up one dir, main page]

MX2017014142A - Mycobacterium recombinante como un agente inmunoterapeutico para el tratamiento de cancer. - Google Patents

Mycobacterium recombinante como un agente inmunoterapeutico para el tratamiento de cancer.

Info

Publication number
MX2017014142A
MX2017014142A MX2017014142A MX2017014142A MX2017014142A MX 2017014142 A MX2017014142 A MX 2017014142A MX 2017014142 A MX2017014142 A MX 2017014142A MX 2017014142 A MX2017014142 A MX 2017014142A MX 2017014142 A MX2017014142 A MX 2017014142A
Authority
MX
Mexico
Prior art keywords
cancer treatment
recombinant
agent
immunotherapeutical
mycobacterium
Prior art date
Application number
MX2017014142A
Other languages
English (en)
Other versions
MX389038B (es
Inventor
Grode Leander
Original Assignee
Vakzine Projekt Man Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vakzine Projekt Man Gmbh filed Critical Vakzine Projekt Man Gmbh
Publication of MX2017014142A publication Critical patent/MX2017014142A/es
Publication of MX389038B publication Critical patent/MX389038B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4524—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01005—Urease (3.5.1.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se relaciona con una célula de Mycobacterium recombinante para su uso como un agente inmunoterapéutico en el tratamiento de cáncer, particularmente en el tratamiento de tumores sólidos. Más particularmente, la invención se relaciona con la inmunoterapia de carcinoma de vejiga.
MX2017014142A 2015-05-04 2016-05-03 Mycobacterium recombinante como un agente inmunoterapeutico para el tratamiento de cancer. MX389038B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166206.1A EP3090757A1 (en) 2015-05-04 2015-05-04 Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
US201562387407P 2015-12-23 2015-12-23
PCT/EP2016/059872 WO2016177717A1 (en) 2015-05-04 2016-05-03 Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer

Publications (2)

Publication Number Publication Date
MX2017014142A true MX2017014142A (es) 2018-03-15
MX389038B MX389038B (es) 2025-03-20

Family

ID=53054880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014142A MX389038B (es) 2015-05-04 2016-05-03 Mycobacterium recombinante como un agente inmunoterapeutico para el tratamiento de cancer.

Country Status (24)

Country Link
US (2) US10525118B2 (es)
EP (2) EP3090757A1 (es)
JP (1) JP6778697B2 (es)
KR (1) KR102667859B1 (es)
CN (1) CN107864656A (es)
AU (1) AU2016258885B2 (es)
BR (1) BR112017023747A2 (es)
CA (1) CA2984602C (es)
CU (1) CU20170138A7 (es)
CY (1) CY1123754T1 (es)
DK (1) DK3291831T3 (es)
EA (1) EA036492B1 (es)
ES (1) ES2845724T3 (es)
HR (1) HRP20210107T1 (es)
HU (1) HUE052711T2 (es)
IL (1) IL255303B (es)
LT (1) LT3291831T (es)
MX (1) MX389038B (es)
PH (1) PH12017502011A1 (es)
PL (1) PL3291831T3 (es)
PT (1) PT3291831T (es)
RS (1) RS61333B1 (es)
SI (1) SI3291831T1 (es)
WO (1) WO2016177717A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022203308A1 (ko) * 2021-03-22 2022-09-29 클립스비엔씨 주식회사 신규한 재조합 마이코박테리움 스메그마티스 균주 및 이의 용도
US20240277825A1 (en) * 2021-07-22 2024-08-22 Serum Life Science Europe Gmbh Recombinant Mycobacterium as an Immunotherapeutic Agent for the Second-Line Therapy of Bladder Carcinoma
MX2024000980A (es) * 2021-07-22 2024-06-21 Serum Life Science Europe Gmbh Mycobacterium recombinante como un agente inmunoterapeutico para la terapia de segunda linea contra carcinoma de vejiga urinaria.
EP4122491A1 (en) * 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733151A (en) 1996-08-23 1998-03-31 Edsall; David Electrical clamping connection device
DE602004028000D1 (de) 2003-04-23 2010-08-19 Max Planck Gesellschaft Tuberkulose vaccine mit verbesserter effizienz
AU2014210617B2 (en) * 2004-10-21 2016-07-21 Vakzine Projekt Management Gmbh Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
KR101907222B1 (ko) 2010-09-20 2018-10-11 바크지네 프로제크트 마나게멘트 게엠베하 인간에게 사용하기 위한 백신으로서 재조합 마이코박테리움
KR101832019B1 (ko) 2010-12-21 2018-02-23 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 백신으로서의 재조합 마이코박테리움
EP3502702A3 (en) * 2011-06-10 2019-07-10 Deutsches Krebsforschungszentrum Prediction of recurrence for bladder cancer by a protein signature in tissue samples
EP2620159A1 (en) * 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria

Also Published As

Publication number Publication date
US11426453B2 (en) 2022-08-30
MX389038B (es) 2025-03-20
HK1247574A1 (en) 2018-09-28
KR20170140328A (ko) 2017-12-20
CA2984602C (en) 2023-09-05
EP3291831B1 (en) 2020-12-30
EP3090757A1 (en) 2016-11-09
CA2984602A1 (en) 2016-11-10
PL3291831T3 (pl) 2021-05-31
LT3291831T (lt) 2021-02-25
PH12017502011A1 (en) 2018-03-26
CY1123754T1 (el) 2022-05-27
HUE052711T2 (hu) 2021-05-28
CN107864656A (zh) 2018-03-30
US10525118B2 (en) 2020-01-07
EA201792412A1 (ru) 2018-03-30
EP3291831A1 (en) 2018-03-14
PT3291831T (pt) 2021-01-26
IL255303A0 (en) 2017-12-31
BR112017023747A2 (pt) 2018-07-31
SI3291831T1 (sl) 2021-03-31
EA036492B1 (ru) 2020-11-17
DK3291831T3 (da) 2021-01-18
ES2845724T3 (es) 2021-07-27
IL255303B (en) 2021-08-31
HRP20210107T1 (hr) 2021-03-19
WO2016177717A1 (en) 2016-11-10
US20200179502A1 (en) 2020-06-11
AU2016258885A1 (en) 2017-11-23
US20180200357A1 (en) 2018-07-19
KR102667859B1 (ko) 2024-05-21
JP6778697B2 (ja) 2020-11-04
RS61333B1 (sr) 2021-02-26
JP2018520643A (ja) 2018-08-02
CU20170138A7 (es) 2018-04-03
AU2016258885B2 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
CL2023000812A1 (es) Péptidos, combinaciones y andamiajes para uso en inmunoterapia contra el cáncer divisional de solic.2017-02448
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
ZA202004557B (en) Modulatory polynucleotides
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
BR112018005937A2 (pt) conjugados de oligonucleotídeo de afinidade e usos destes
ECSP17073743A (es) Moduladores de k-ras
LT3331900T (lt) Peptidai ir peptidų derinys, skirti naudoti imunoterapijai gydant prostatos vėžį ir kitų rūšių vėžį
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
PH12016502479A1 (en) Formulated receptor polypeptides and related methods
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
TW201613648A (en) Compounds and compositions for immunotherapy
MX2018000267A (es) Combinacion de inhibidores de histona desacetilasa y anticuerpo de ligando 1 de anti-muerte celular programada para el tratamiento de cancer.
CL2017000506A1 (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
CL2018001108A1 (es) Composiciones y métodos para transducción de tumores
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
BR112018010279A2 (pt) novos anticorpos anti-emr2 e métodos de uso
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
CY1123754T1 (el) Ανασυνδιασμενο mycobacterium ως ενας ανοσοθεραπευτικος παραγοντας για τη θεραπεια του καρκινου
HUE047540T2 (hu) Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
BR112018012883A2 (pt) novos anticorpos anti-upk1b e métodos de uso
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
BR112018068798A2 (pt) composições e métodos para tratamento de doenças parasíticas